Doctorly GmbH raised $10 million in a series A funding round to revamp the German health care sector, giving medical staff new tools to eliminate disk operating systems (DOS).
Vivasure Medical Ltd. received a €30 million (US$32 million) strategic investment from Haemonetics Corp. to help develop its Perqseal closure device system which manages bleeding complications associated with large-bore arterial vessel closure. Haemonetics has an option to buy Vivasure upon the completion of the company achieving certain milestones.
Siyi Intelligence Technology Co. Ltd. raised nearly $15 million in a series A funding round to speed up the development of its smart rehabilitation products and of its neurorehabilitation solutions and build a digital rehabilitation service platform.
Precision oncology startup Prana Thoracic Inc. closed a $3 million series A financing round aimed at advancing its minimally invasive lung tissue excision device for early treatment of lung cancer. The series A funds and a prior $3 million award from the Cancer Prevention & Research Institute of Texas are earmarked for product development and to support first-in-human clinical studies.
Feops NV hopes to raise €10 million (US$10.67 million) in a series C fundraising round that will allow the company to scale up its operations worldwide. This follows the release of a study in JACC: Cardiovascular Interventions which revealed that its cloud-based platform, Feops Heartguide, significantly improved efficiency and outcomes of left atrial appendage closure (LAAC) procedures.
Current Surgical Inc. secured $3.2 million in a seed funding round to support development of its surgical needle platform to precisely destroy unresectable tumors. True Ventures led the round with participation from 1517 Fund and Scifounders.
Visionhealth GmbH will use the €3 million (US$3.2 million) it recently raised in a pre-series A financing to conduct a clinical trial on its digital health app designed to provide more accurate dosing of treatments for chronic obstructive pulmonary disease (COPD) and asthma.
Affluent Medical SA reported the imminent raising of nearly $14 million to fund development throughout 2023 of its implantable medical devices for treating urinary incontinence and heart valve pathology. Affluent, quoted on the Paris Euronext stock exchange since 2021, issued new shares accompanied by redeemable share warrants with shareholder preferential subscription rights being preserved.
Creo Medical Group plc is on its way to being cash flow breakeven and profitable following a successful fundraise, which will accelerate the rollout of its suite of electrosurgical products, CEO Craig Gulliford told BioWorld.
Previa Medical SA will begin clinical trials later this year of its artificial intelligence software designed for early detection of sepsis after it raised €2.1 million (US $2.2 million) in seed funds.
